secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001104659-24-074078
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports positive Phase 1 data for ENTR-601-44; plans Phase 2 trials in Q4 2024
--------------------------------------------------------------------------------

- No serious or drug-related adverse events; ENTR-601-44 well-tolerated across all 4 dose cohorts (0.75-6 mg/kg) in 32 healthy volunteers.
- At 6 mg/kg, mean exon skipping 0.44% (range 0.3-0.65%), statistically significant vs placebo (p<0.005); muscle concentration mean 53.8 ng/g.
- Plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 (exon 44) and ENTR-601-45 (exon 45).
- ENTR-601-50 Phase 2 trial filing expected in 2025; company sees potential for dosing intervals of at least six weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/0001104659-24-074078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/tm2417848d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-074078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer